Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.14694
Abstract: Key Points Question Are commonly used treatments for metastatic castration-resistant prostate cancer (mCRPC) associated with a decline in cognitive function in older men? Findings This cohort study followed up 198 men aged 65 years or… read more here.
Keywords: older men; prostate cancer; metastatic castration; castration resistant ... See more keywords
MiR‐15b‐5p inhibits castration‐resistant growth of prostate cancer cells by targeting the muscarinic cholinergic receptor CHRM3
Sign Up to like & getrecommendations! Published in 2023 at "FEBS Letters"
DOI: 10.1002/1873-3468.14598
Abstract: Cholinergic receptor muscarinic 3 (CHRM3)‐mediated focal adhesion kinase/YES‐associated protein (YAP) signalling is essential for the growth of castration‐resistant prostate cancer (CRPC) cells. Here, we evaluated the molecular mechanisms through which CHRM3 overexpression facilitates castration‐resistant growth.… read more here.
Keywords: prostate cancer; growth; mir 15b; castration resistant ... See more keywords
AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12529
Abstract: The androgen receptor splice variant (AR‐V) 7 in circulating tumor cells (CTCs) is a predictor for resistance to anti‐AR‐targeted treatment, but not to taxane‐based chemotherapy in metastatic castration‐resistant prostate cancer (mCRPC). In this study, we… read more here.
Keywords: prostate; tumor cells; prostate cancer; circulating tumor ... See more keywords
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13320
Abstract: The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate… read more here.
Keywords: prevalence; prostate; resistant prostate; castration resistant ... See more keywords
Preclinical patient-derived modelling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13382
Abstract: The use of mutation analysis of homologous recombination repair (HRR) genes to estimate PARP‐inhibition response may miss a larger proportion of responding patients. Here, we provide preclinical models for castration‐resistant prostate cancer (CRPC) that can… read more here.
Keywords: prostate cancer; castration resistant; patient derived;
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3806
Abstract: Metastatic castration‐resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of… read more here.
Keywords: phase; docetaxel plus; metastatic castration; castration resistant ... See more keywords
Exosomal TUBB3 mRNA expression of metastatic castration‐resistant prostate cancer patients: Association with patient outcome under abiraterone
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.4168
Abstract: To use ddPCR to quantify plasma exosomal class III β‐tubulin (βIII‐tubulin, TUBB3, encoded by the TUBB3 gene) mRNA expression in metastatic castration‐resistant prostate cancer (mCRPC) patients, and study the association of this expression with abiraterone… read more here.
Keywords: expression metastatic; metastatic castration; expression; castration resistant ... See more keywords
Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5262
Abstract: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant… read more here.
Keywords: prostate cancer; resistant prostate; real world; castration resistant ... See more keywords
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5313
Abstract: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration‐resistant prostate cancer (mCRPC) can facilitate shared‐decision making for optimal management. This study sought to elicit patient preferences for mCRPC treatments… read more here.
Keywords: prostate cancer; cancer mcrpc; resistant prostate; castration resistant ... See more keywords
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5333
Abstract: Metastatic castration‐resistant prostate cancer (mCRPC) is a genetically heterogeneous disease with a poor prognosis. The prevalence of mutations in homologous recombination repair (HRR) pathway genes, including BRCA1/2, as well as treatment patterns and clinical outcomes,… read more here.
Keywords: prostate cancer; resistant prostate; castration resistant; metastatic castration ... See more keywords
Differential adoption of castration‐resistant prostate cancer treatment across facilities in a national healthcare system
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5490
Abstract: Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide across facilities in a national healthcare system… read more here.
Keywords: prostate cancer; differential adoption; across facilities; resistant prostate ... See more keywords